Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

A Phase Ib, Open Label, Parallel-Design Single- and Multiple-Dose Study Comparing Modified Release Topiramate Formulations to Immediate Release Formulations of Topiramate Dosed in Combination With Immediate Release Phentermine in Obese Adults

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00518466

Enrollment

Registered

2007-08-20

Start date

2007-07-31

Completion date

2007-12-31

Last updated

2011-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity

Brief summary

The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.

Interventions

DRUGtopiramate

25 mg modified-release capsules

DRUGphentermine

7.5 mg immediate-release capsules

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Obese adults * Body mass index between 30.0 and 42.0 kg/m2 (inclusive) * Medically healthy with no clinically significant results of screening exams

Exclusion criteria

* History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease * History of glaucoma or increased intraocular pressure * History of kidney stones * Cholelithiasis or cholecystitis within 6 months * Cardiovascular event within 6 months * Obesity of known genetic or endocrine origin * Recent weight instability * Use of Very Low Calorie diet or participation in organized weight loss program within 3 months * Systolic blood pressure \> 150 or diastolic \> 95 mm Hg * Positive urine drug or alcohol screen * Positive serology for HIV, HBV, or HCV * History of alcoholism or drug abuse * History of significant psychiatric disease, current depression of moderate or greater severity, any history of suicidal ideation * Hypersensitivity to study drug or related compounds * Use of prescription or OTC medication other than hormonal contraceptive within 14 days prior to first dosing with study drug * Blood donation or significant blood loss within 56 days or plasma donation within 7 days prior to first dosing with study drug * Women who are pregnant or lactating * Hemoglobin \< 12 g/dL * Use of tobacco or nicotine-containing products within 6 months

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic parameters	One month

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026